Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.

Using “cure” to refer to “obtaining a normal life” also fits — if you ignore previously lost education, career opportunities ...

CSL Limited (OTC:CSLLY) and uniQure Inc (NASDAQ:QURE) announced the four-year results from the pivotal HOPE-B study ...

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

With hemophilia, it's easy to assume that joint pain is caused by bleeding. But that's not always the case, columnist G ...

CSL (ASX: CSL; USOTC: CSLLY) has unveiled four-year results from its pivotal HOPE-B study, demonstrating the long-term ...

Hemophilia A patients with self-described problem joints were found to have worse clinical outcomes, with more pain, in a new study.

Global biotechnology leader CSL Behring (ASX:CSL; USOTC: CSLLY (OTC:CSLLY)) announced the four-year results from the HOPE-B ...

Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans ...

Union Minister Dr. Jitendra Singh today launched India’s first indigenous Automated Bio Medical Waste Treatment Plant at ...